Who is sponsoring NCT04019496?

NCT04019496 is sponsored by University Medicine Greifswald.

What drugs are being tested in NCT04019496?

Interventions in NCT04019496: antibodies against calcitonin-gene related peptide or its receptor.

Is NCT04019496 still recruiting?

NCT04019496 is currently completed. Last updated 27 May 2021.

Last reviewed 2021-05-27 · How we verify

NCT04019496

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurophysiology of Prophylactic Treatment in Migraine

Completed Last updated 27 May 2021

What this trial tests

trial testing antibodies against calcitonin-gene related peptide or its receptor in Migraine in 44 participants. Completed in 2 May 2021.

Timeline

29 January 2019

Primary endpoint
2 May 2021

2 May 2021

Quick facts

Lead sponsor	University Medicine Greifswald
Status	Completed
Study type	OBSERVATIONAL
Enrollment	44
Start date	29 January 2019
Primary completion	2 May 2021
Estimated completion	2 May 2021
Sites	1 location across Germany

Drugs / interventions tested

antibodies against calcitonin-gene related peptide or its receptor — full drug profile →

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

University Medicine Greifswald

Who can join

18 and older, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to improve the pathophysiological understanding of migraine in in a longitudinal observational study investigating changes of established neurophysiological and imaging parameters in line with changes of the clinical phenotype. The study's focus is the investigation of mechanisms that are directly related to the cyclic character of migraine and its core structures. In this context, the primary endpoint is a change in the nociceptive blink reflex, an established brain stem reflex to study the trigemino-spinal system, associated with changes in migraine frequency and severity. In order to reliably detect changes in the trigeminal pain system, investigations are performed in patients before starting a prophylactic therapy and 3 months afterwards. Several secondary endpoints are used to evaluate changes of multimodal sensory and cortical information processing. Cerebral imaging will include examinations of structural and network effects of altered migraine disease activity.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study.
Thiele A, Klehr L, Strauß S, Angermaier A, et al · · 2021 · cited 8× · PMID 34895133 · DOI 10.1186/s10194-021-01364-x
Three-Month Treatment with Monoclonal Antibodies Targeting the CGRP Pathway Is Associated with Multi-Domain Changes in Sensory Processing and Cortical Network Efficiency in Migraine: Results from a Prospective Case-Control Study.
Klehr L, Thiele A, Bendig M, Kloetzer C, et al · · 2026 · PMID 42193323 · DOI 10.3390/biomedicines14050996
„Wissen schaffen – Wissen leben“
· 2021
Preventive Treatment With CGRP Monoclonal Antibodies Restores Brain Stem Habituation Deficits and Excitability to Painful Stimuli in Migraineurs: Results From a Prospective Case-control Study
Thiele A, Klehr L, Strauß S, Angermaier A, et al · · 2021 · DOI 10.21203/rs.3.rs-951359/v1

Verify or expand the search:

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other University Medicine Greifswald trials

Trials by the same sponsor.

NCT06796374 — A Comparison of Fisetin Kinetics in Young and Old Adults · NA · recruiting
NCT06970171 — Acceptance of Mandibular Advancement Devices · NA · not yet recruiting
NCT06939608 — Kinetics of Yohimbine in Humans to Explore Sex and CYP2D6 Genotype Interactions · NA · completed
NCT06273241 — Impact of Food Intake on Berberine Kinetics · NA · completed
NCT06249451 — Staphylococcus Aureus Bacteraemia (SAB)-Support-Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04019496 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medicine Greifswald
Last refreshed: 27 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04019496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing